---
title: "ACRS.US (ACRS.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/ACRS.US/news.md"
symbol: "ACRS.US"
name: "ACRS.US"
parent: "https://longbridge.com/en/quote/ACRS.US.md"
datetime: "2026-05-20T08:19:09.969Z"
locales:
  - [en](https://longbridge.com/en/quote/ACRS.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ACRS.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ACRS.US/news.md)
---

# ACRS.US (ACRS.US) — Related News

### [Aclaris Therap | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 1.996 M](https://longbridge.com/en/news/285620105.md)
*2026-05-07T21:06:25.000Z*
### [Why Is Phoenix Asia Stock Gaining Today?](https://longbridge.com/en/news/285586426.md)
*2026-05-07T16:05:37.000Z*
> Phoenix Asia Holdings Limited shares rose 0.19% on Thursday following the announcement of a $1 billion stock acquisition

### [Aclaris Therapeutics (ACRS) Gets a Buy from Craig-Hallum](https://longbridge.com/en/news/285566579.md)
*2026-05-07T13:55:45.000Z*
> Craig-Hallum analyst Adam Vogel has maintained a Buy rating on Aclaris Therapeutics (ACRS) with a price target of $10.00

### [Aclaris Therap | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 1.996 M](https://longbridge.com/en/news/285538634.md)
*2026-05-07T11:18:16.000Z*
### [Aclaris Therapeutics (NASDAQ:ACRS) Stock Rating Upgraded by Guggenheim](https://longbridge.com/en/news/285357913.md)
*2026-05-06T10:40:43.000Z*
> Guggenheim has upgraded Aclaris Therapeutics (NASDAQ: ACRS) to a "strong-buy" rating. The stock has seen mixed ratings f

### [This Applied Materials Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday](https://longbridge.com/en/news/285240940.md)
*2026-05-05T16:36:05.000Z*
> Top Wall Street analysts have initiated coverage on several companies with varying ratings. Seaport Global's Jay Goldber

### [Aclaris Therapeutics Updates ATI-052 Phase 1 Data, Picks ATI-2138 for Phase 2b in Lichen Planus](https://longbridge.com/en/news/284405693.md)
*2026-04-28T14:17:49.000Z*
> Aclaris Therapeutics (NASDAQ: ACRS) announced updates on its clinical programs, revealing full results from the Phase I-